Incorporation of novel therapies for the treatment of acute myeloid leukemia: A perspective Review

Authors: Waksal, J. A.; Tallman, M. S.
Review Title: Incorporation of novel therapies for the treatment of acute myeloid leukemia: A perspective
Abstract: Acute myeloid leukemia (AML) is a heterogeneous group of diseases that poses an array of therapeutic challenges. For decades two chemotherapeutic agents, cytarabine and daunorubicin, remained the backbone of AML therapy protocols. However, since 2017 nine novel therapies have been approved for the management of AML. With the rapid expansion of therapeutic options, hematologists must adapt their practice to optimize the benefits of these novel therapy options and minimize treatment toxicity. Here, we discuss the novel therapies that have changed the standard of care in management of patients with AML. We summarize the pivotal clinical trials that lead to the approval of these agents, and ongoing trials evaluating additional potential indications. We discuss several promising therapy candidates and their corresponding clinical trials. We discuss therapeutic strategies to incorporate these therapies into practice and pose unanswered questions that have arisen along with the expansion of treatment options. © 2021 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: cancer chemotherapy; gene mutation; review; treatment; antineoplastic agent; protein bcl 2; maintenance therapy; health care quality; flt3 ligand; azacitidine; drug formulation; therapies; aml; acute myeloid leukemia; novel; hematologist; consolidation chemotherapy; human; priority journal; hedgehog signaling; cytarabine plus daunorubicin; antibody drug conjugate; isocitrate dehydrogenase inhibitor; magrolimab; new treatments
Journal Title: Leukemia and Lymphoma
Volume: 62
Issue: 4
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2021-01-01
Start Page: 779
End Page: 790
Language: English
DOI: 10.1080/10428194.2020.1842403
PUBMED: 33541192
PROVIDER: scopus
Notes: Review -- Export Date: 3 May 2021 -- Source: Scopus
Citation Impact
MSK Authors
  1. Martin Stuart Tallman
    561 Tallman
  2. Julian Waksal
    1 Waksal